Alligator Bioscience AB - ESG Rating & Company Profile powered by AI
The webpage is a zero-cost ESG assessment for Alligator Bioscience AB. Alternative companies in the scoring industry group for Alligator Bioscience AB are displayed. The report of Alligator Bioscience AB is prepared by All Street Sevva using cutting edge NLP.
Alligator Bioscience AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.6; made up of an environmental score of 5.3, social score of 6.4 and governance score of 8.0.
6.6
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
337 | Sonoma Pharmaceuticals Inc | 6.7 | High |
337 | Zhong Yuan Bio-Technology Holdings Ltd | 6.7 | High |
389 | Alligator Bioscience AB | 6.6 | High |
389 | Austar Lifesciences Ltd | 6.6 | High |
389 | Daiichi Sankyo Co Ltd | 6.6 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Alligator Bioscience AB have an accelerator or VC vehicle to help deliver innovation?
Does Alligator Bioscience AB disclose current and historical energy intensity?
Does Alligator Bioscience AB report the average age of the workforce?
Does Alligator Bioscience AB reference operational or capital allocation in relation to climate change?
Does Alligator Bioscience AB disclose its ethnicity pay gap?
Does Alligator Bioscience AB disclose cybersecurity risks?
Does Alligator Bioscience AB offer flexible work?
Does Alligator Bioscience AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Alligator Bioscience AB disclose the number of employees in R&D functions?
Does Alligator Bioscience AB conduct supply chain audits?
Does Alligator Bioscience AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Alligator Bioscience AB conduct 360 degree staff reviews?
Does Alligator Bioscience AB disclose the individual responsible for D&I?
Does Alligator Bioscience AB disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Alligator Bioscience AB disclose current and / or historical scope 2 emissions?
Does Alligator Bioscience AB disclose water use targets?
Does Alligator Bioscience AB have careers partnerships with academic institutions?
Did Alligator Bioscience AB have a product recall in the last two years?
Does Alligator Bioscience AB disclose incidents of discrimination?
Does Alligator Bioscience AB allow for Work Councils/Collective Agreements to be formed?
Has Alligator Bioscience AB issued a profit warning in the past 24 months?
Does Alligator Bioscience AB disclose parental leave metrics?
Does Alligator Bioscience AB disclose climate scenario or pathway analysis?
Does Alligator Bioscience AB disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Alligator Bioscience AB disclose the pay ratio of women to men?
Does Alligator Bioscience AB support suppliers with sustainability related research and development?
Does Alligator Bioscience AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Alligator Bioscience AB reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Alligator Bioscience AB involved in embryonic stem cell research?
Does Alligator Bioscience AB disclose GHG and Air Emissions intensity?
Does Alligator Bioscience AB disclose its waste policy?
Does Alligator Bioscience AB report according to TCFD requirements?
Does Alligator Bioscience AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Alligator Bioscience AB disclose energy use targets?
Does Alligator Bioscience AB disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Alligator Bioscience AB have a policy relating to cyber security?
Have a different question?
Potential Risks for Alligator Bioscience AB
These potential risks are based on the size, segment and geographies of the company.
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.